Clinical Trial Update: Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial comparing switching to a two-drug regimen DTG/3TC versus continuing a three-drug regimen (BIC/FTC/TAF or DTG/3TC/ABC) in people living …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE)
• Dovato (dolutegravir/lamivudine)
• Triumeq (dolutegravir/abacavir/lamivudine)

Snippet

Sponsor: José Antonio Mata Marín | Conditions: HIV Infections | Phase 4 | Status: RECRUITING